On the other hand, patients with mutated DNMT3A or IDH2 had been shown to have worse overall survival and more rapid progression to AML, compared to patients with wild-type DNMT3A or IDH27, 26-28. This evidence concerns the gene IDH2 and acute myeloid leukemia.